Fatty Acid Synthase (FASN) catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids. In some cancer cell lines, this protein has been found to be fused with estrogen receptor-alpha (ER-alpha), in which the N-terminal of FASN is fused in-frame with the C-terminal of ER-alpha. FASN is highly expressed in adipocytes and liver. FASN is a central enzyme in de novo lipogenesis. FASN is a target for SREBP and is upregulated by LXR activation, it is also one of the accepted markers for insulin resistance, SREBP and LXR activation. FASN: Bovine: 2513aa, Pig: 2411aa, Chick: 2511aa, Mouse: 2504aa, Rat: 2505aa, Human: 2511aa, 273.4kD, 17q25. Expression: Ubiquitous, more prominent expression in brain, lungs, and liver. Source: Synthetic peptide corresponding to 18aa of ~N-termial of human FASN (KLH) (P49327). Applications: Suitable for use in ELISA and Antibody Blocking. Other applications not tested. Recommended Dilution: ELISA: 50-100ng. Antibody Blocking: 5-10ug/1ug of Affinity Purified antibody or 1ul of serum. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
